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Indications for revascularisation, PCI vs CABG: a case 
for physiology-guided PCI with next-generation DES
The guidelines state a class III level of evidence (LoE) B 
recommendation against percutaneous coronary interven-
tion (PCI) in patients with left main disease with a high 
SYNTAX score (> 32) and three-vessel disease with inter-
mediate (23–32) and high SYNTAX scores. There appears 
to be insufficient evidence to support this recommendation, 
given the fact that this is based on only one trial (SYNTAX) 
in which first-generation drug-eluting stents (DES) were 
used, which are currently no longer used as they have been 
superseded by next-generation DES that proved to be supe-
rior in terms of repeat revascularisation, stent thrombosis, 
myocardial infarction and even death [3, 4].
The fact that the guideline advocates assigning PCI or 
coronary artery bypass grafting (CABG) based upon the 
purely anatomical SYNTAX score foregoes other impor-
tant clinical and functional factors that are considered by 
the typical heart team in the Netherlands. The importance 
of functional lesion assessment using coronary pressure or 
flow is not taken into account by the current recommenda-
tion. The FAME trials clearly demonstrated the usefulness 
of fractional flow reserve (FFR)-guided revascularisation 
in patients with multi-vessel disease [5]. An opportunity to 
deliver the important message that interrogation, with FFR, 
of all PCI targets in multi-vessel disease results in better 
patient outcome is therefore missed. Interrogation of all tar-
get stenoses with FFR is also important because it allows 
calculation of the functional SYNTAX score, which has 
been shown to be superior to the standard SYNTAX score 
in terms of risk stratification of patients with multi-vessel 
coronary artery disease undergoing PCI [6]. Specifically, 
by only counting lesions that are FFR-positive towards the 
total of the SYNTAX score, patients can often be assigned 
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Introduction: the European guidelines from a Dutch 
perspective
The recently updated 2014 European Society of Cardiol-
ogy (ESC)/European Association for Cardio-Thoracic Sur-
gery (EACTS) guidelines on myocardial revascularisation 
provide a framework for decision-making in daily clinical 
practice [1]. This work requiring an enormous amount of 
deliberation and discussion by the guideline committee is 
greatly appreciated. Nonetheless, there are a few recom-
mendations in the current guideline that are not ideally 
suited to the specific context of myocardial revascularisa-
tion in the Netherlands, where decision-making using a 
heart team consisting of a cardiologist and a cardiothoracic 
surgeon is deep-rooted [2]. In this document, an addendum 
to the guidelines is proposed to consolidate these differ-
ences between clinical practice in the Netherlands and the 
broader European context.
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to a lower-risk category. Currently ongoing studies such as 
FAME 3, SYNTAX II, IFR-SWEDEHEART and DEFINE-
FLAIR are designed to further refine the use of physiologi-
cal-guided revascularisation based on FFR or instantaneous 
wave-free ratio (iFR) in the treatment of multi-vessel coro-
nary artery disease.
Therefore, the final decision on PCI or CABG in com-
plex multi-vessel disease should be made by the heart team 
whilst taking into account state-of-the art techniques and 
devices, functional lesion assessment and the specific pref-
erences of individual patients.
Early invasive strategy in non-ST-elevation ACS
The guidelines recommend an early invasive strategy in 
patients with non-STE acute coronary syndromes (ACS) 
in all patients with at least one primary high-risk crite-
rion (GRACE score > 140, relevant rise or fall in troponin 
or dynamic ST-segment or T-wave changes). This class I 
recommendation is supported with an LoE A based upon 
one individual randomised trial and one meta-analysis [7, 
8]. However, the TIMACS trial only showed a reduction 
in a composite endpoint of death, myocardial infarction or 
stroke in patients with a high GRACE score, which was a 
finding from a negative trial and should therefore be inter-
preted with caution. Although one meta-analysis reported 
a reduction in secondary endpoints (recurrent ischaemia, 
length of hospital stay), there was no reduction in hard clini-
cal endpoints [8]. This was confirmed in another meta-anal-
ysis [9]. Therefore, the early invasive strategy seems to hold 
no clear benefit over the invasive strategy within 72 hours.
Recommendations for daily clinical practice in the 
Netherlands
The recently updated guideline on myocardial revasculari-
sation presents a framework for daily clinical practice, but 
parts of this guideline cannot be directly applied to daily 
clinical practice in the Netherlands. We propose the follow-
ing alternative recommendations:
Recommendation for the type of revascularisation 
(CABG or PCI) in patients with stable coronary artery dis-
ease with suitable coronary anatomy for both procedures 
and low predicted surgical mortality:
Regardless of the extent of coronary artery disease, the 
decision should be made by the heart team based on the 
patient’s clinical characteristics, procedural risk (e.g. calcu-
lated by Euroscore II or similar risk score models), severity 
and distribution of coronary artery disease and preferably 
invasive physiological assessment of all lesions.
Recommendation for invasive evaluation and revascu-
larisation in NSTE-ACS:
An invasive strategy is recommended (<72 h after initial 
presentation) in patients with at least one high-risk criterion 
or recurrent symptoms. High-risk criteria are: relevant rise 
or fall in troponin, dynamic ST-segment or T-wave changes, 
intermediate to high GRACE score, diabetes mellitus, renal 
insufficiency (eGFR <60 ml/min/1.73 m2), left ventricular 
ejection fraction <40 %, early post-infarction angina, recent 
PCI and prior CABG. There is currently insufficient evi-
dence to support an early invasive strategy (<24 h), with an 
exception for patients with an indication for urgent coronary 
angiography (refractory angina, heart failure, cardiogenic 
shock, life-threatening ventricular arrhythmias or haemody-
namic instability).
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